Hall Adrian, Abendroth Jan, Bolejack Madison J, Ceska Tom, Dell'Aiera Sylvie, Ellis Victoria, Fox David, François Cyril, Muruthi Muigai M, Prével Camille, Poullennec Karine, Romanov Sergei, Valade Anne, Vanbellinghen Alain, Yano Jason, Geraerts Martine
UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium.
UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States.
ACS Med Chem Lett. 2022 Jun 25;13(7):1099-1108. doi: 10.1021/acsmedchemlett.2c00134. eCollection 2022 Jul 14.
We describe the identification and characterization of a series of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1. The initial hit was identified via a high-throughput screening and represents a rare example of a covalent inhibitor which acts via an SAr reaction of a 2,5-dichloropyrimidine with a cysteine residue (Cys440). The covalent mechanism of action was supported by biochemical experiments and was confirmed by mass spectrometry. Ultimately, the displacement of the 2-chloro moiety was confirmed by crystallization of an inhibitor with the CTKD. We also disclose the crystal structures of three compounds from this series bound to the CTKD of MSK1, in addition to the crystal structures of two unrelated RSK2 covalent inhibitors bound to the CTKD of MSK1.
我们描述了一系列MSK1 C末端激酶结构域(CTKD)共价抑制剂的鉴定和特性。最初的命中化合物是通过高通量筛选鉴定出来的,它代表了一种罕见的共价抑制剂,通过2,5-二氯嘧啶与半胱氨酸残基(Cys440)的SAr反应起作用。生化实验支持了共价作用机制,并通过质谱法得到证实。最终,通过抑制剂与CTKD的结晶证实了2-氯部分的取代。除了两种与MSK1的CTKD结合的不相关RSK2共价抑制剂的晶体结构外,我们还披露了该系列中三种与MSK1的CTKD结合的化合物的晶体结构。